Business Overview
Incorporated in 2000, Molbio Diagnostics Limited has emerged as one of India’s leading molecular diagnostics companies, with a strong focus on developing rapid, point-of-care testing solutions for infectious and non-communicable diseases. The company has built its business around its proprietary Truenat platform, a portable, battery-operated PCR-based molecular diagnostics system capable of delivering laboratory-quality results within an hour, making advanced diagnostics accessible even in resource-constrained settings.
Over the years, Molbio has transformed from a tuberculosis-focused diagnostics player into a diversified healthcare technology company. Its portfolio today comprises 43 diagnostic assays covering more than 30 diseases, including tuberculosis, COVID-19, HIV, Hepatitis B & C, HPV and several antimicrobial resistance tests. Beyond molecular diagnostics, the company has expanded into digital pathology, radiology and breast cancer screening solutions through strategic acquisitions and partnerships, creating multiple growth avenues beyond its core business.
The company manufactures its products through six facilities in India and supplies diagnostic solutions to governments, hospitals, laboratories and global healthcare agencies across more than 90 countries. Its innovation-led business model is supported by extensive in-house R&D, a strong intellectual property portfolio and multiple international certifications, enabling continuous product development and global commercialisation.
IPO Synopsis
| Particulars | Details |
|---|---|
| IPO Date | August 10, 2026 to August 12, 2026 |
| Face Value | ₹1 per share |
| Price Band | ₹768 to ₹807 per share |
| Lot Size | 18 shares and in multiples thereof |
| Issue Size | ₹940 crore |
| Fresh Issue | ₹200 crore |
| Offer for Sale | ₹740 crore |
Objective of the Issue
-
Setting Up Research and Development Infrastructure
The company intends to utilise ₹125.12 crore towards funding capital expenditure for setting up infrastructure for a research and development facility, Centre of Excellence and connected office space. -
Purchase of Plant, Machinery and Equipment
The company intends to utilise ₹80.81 crore towards the purchase of certain plant, machinery and other equipment for Goa Unit I, Goa Unit II and the Visakhapatnam Unit. -
General Corporate Purposes
A portion of the net proceeds from the fresh issue will be used for general corporate purposes.
Strengths
-
Proprietary Truenat Platform Carrying WHO Endorsement
Truenat is a portable, battery-operated PCR system pairing the Trueprep sample preparation device with the Truelab analyser to deliver molecular results in roughly an hour outside a conventional laboratory. The company states that it is the only rapid molecular tuberculosis test developed by an Indian company and one of only two worldwide endorsed by the WHO for initial tuberculosis diagnosis and rifampicin resistance detection. That endorsement is a key commercial advantage. More than 12,500 devices have been sold across over 90 countries, creating an installed base that competitors cannot quickly replicate. -
Closed-System Razor-and-Blade Economics
Once a customer buys a Truenat workstation, the disease-specific chips, cartridges and reagents must be purchased from Molbio, creating a closed system that converts each device sale into recurring revenue. Test kit revenue reached ₹1,034.82 crore in FY26, up 41.6%, and now dominates product revenue, while device revenue was broadly flat at ₹203.28 crore even as unit sales rose from 2,180 to 2,524. This divergence reflects the intended business model, where hardware serves as the entry point and consumables generate the recurring economics. As the installed base expands, revenue quality may improve because kit demand is linked to testing volumes rather than fresh capital procurement. -
Portfolio Broadening into Adjacent Diagnostics
Molbio is extending beyond molecular diagnostics into imaging and pathology. It holds a 65.47% stake in Prognosys Medical Systems, which operates in radiology, acquired a controlling stake in California-based OptraScan Inc. in November 2025 for digital pathology, retains an associate stake in Chayagraphics in India and collaborates with UE Life Sciences on breast health screening. The strategic objective is to offer a wider diagnostics portfolio through the same government and institutional channels already established by Truenat.
Risks
-
Dependence on Government and Aid Agency Funding
Revenue from Indian central and state governments and international aid agencies accounted for 84.56%, 87.83% and 91.60% of revenue from the sale of finished goods in Fiscals 2026, 2025 and 2024 respectively. Molbio is therefore highly dependent on public health budgets rather than a diversified commercial market. A change in procurement policy, stretched tender cycles, redesign of the national tuberculosis programme or reduction in donor funding could directly affect revenue. -
Tuberculosis Concentration Is Deepening
Revenue from tuberculosis test kits represented 70.20%, 69.11% and 62.40% of finished goods revenue in Fiscals 2026, 2025 and 2024 respectively. Despite having 43 commercialised assays across more than 30 diseases, the business has become more dependent on tuberculosis-related revenue over the last three years. -
Customer Concentration in a Handful of Institutional Buyers
Revenue from the top 10 customers accounted for 83.26%, 83.62% and 78.54% of finished goods revenue in Fiscals 2026, 2025 and 2024 respectively. With a large portion of the business dependent on a few institutional buyers, negotiating leverage generally remains with customers, pricing is determined through tenders rather than solely by brand strength, and the loss or deferral of a single major relationship could materially affect revenue.
Financial Snapshot
| Particulars (₹ crore) | FY26 | FY25 | FY24 |
|---|---|---|---|
| Total Income | 1,455 | 1,027 | 840 |
| YoY Growth | 41.7% | 22.3% | – |
| EBITDA | 328 | 257 | 185 |
| EBITDA YoY Growth | 27.9% | 38.7% | – |
| EBITDA Margin | 22.6% | 25.0% | 22.0% |
| Profit After Tax | 164 | 138 | 83 |
| PAT YoY Growth | 18.8% | 66.3% | – |
| PAT Margin | 11.3% | 13.4% | 9.9% |
| ROE | 14.3% | 14.5% | 10.3% |
| ROCE | 21.1% | 23.9% | 18.8% |
| ROA | 7.6% | 9.4% | 6.8% |
Conclusion
India’s molecular diagnostics industry is entering a structural growth phase, driven by increasing disease burden, higher penetration of point-of-care testing and greater government focus on early diagnosis of infectious diseases. Within this backdrop, Molbio Diagnostics has established a differentiated position through its proprietary Truenat platform, one of only two WHO-endorsed rapid molecular tuberculosis testing platforms globally. Its installed base of over 12,500 devices across more than 90 countries, coupled with a closed-system consumables model, provides recurring revenue visibility and creates a strong competitive moat. The company is also broadening its addressable market through expansion into digital pathology, radiology and breast health screening, reducing its dependence on a single diagnostics platform over the long term.
Financially, the company has delivered healthy growth, with revenue increasing from ₹840 crore in FY24 to ₹1,455 crore in FY26, while PAT nearly doubled to ₹164 crore. Although EBITDA and PAT margins moderated in FY26 due to business expansion, return ratios remain healthy, with ROCE above 21%, reflecting efficient capital deployment. However, investors should monitor the company’s high dependence on government procurement, tuberculosis-related revenues and a concentrated institutional customer base, which could lead to earnings volatility if procurement cycles slow.
Overall, Molbio combines strong technology leadership, recurring consumable-driven revenues, an expanding global presence and favourable industry tailwinds. Despite customer concentration and government procurement risks, its differentiated business model and growth prospects make the IPO attractive. We recommend this IPO for listing gains.
